Clinical trials: Idarubicin
Leukemia
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
The goal of this clinical research study is to learn if the combination of clofarabine, idarubicin, and cytarabine, or the combination of fludarabine, idarubicin, and cytarabine can help control Acute myeloid leukemia (AML) and…
- Trial name
- NCT01289457
- Testing
- Clofarabine, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- NCT00067028
- Testing
- Clofarabine 40mg/m^2, Idarubicin 10mg/m^2, Ara-C 0.75 g/m^2
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
This phase I/II trial is studying the side effects and best dose of tipifarnib when given with idarubicin and cytarabine and to see how well it works in treating patients with newly diagnosed myelodysplastic syndromes or acute…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00096122
- Testing
- cytarabine, idarubicin, tipifarnib
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
This randomized phase II trial studies how well choline magnesium trisalicylate with idarubicin and cytarabine works in treating patients with acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT02144675
- Testing
- choline magnesium trisalicylate, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Rutgers, The State University of New Jersey
Novo Acute Myeloid Leukemia
Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Acute myeloid leukemia (AML) is a neoplasm of immature hematopoietic cells (blasts) with altered ripening capacity. Due to excessive proliferation, the blasts displace normal hematopoietic cells and bone marrow failure appears.
- Trial name
- NCT01698879
- Testing
- Mylotarg
- Where
- 6 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
AML, Acute Myeloid Leukemia
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
A primary goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with idarubicin and Ara-C for the treatment of acute myelogenous leukemia (AML) and high-risk…
- Conditions
- AML, Acute Myeloid Leukemia, Myelodysplastic Disorders
- Trial name
- NCT00542971
- Testing
- Idarubicin, Sorafenib, Ara-C
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00534469
- Testing
- aldesleukin, filgrastim, busulfan
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Acute Promyelocytic Leukemia
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.
- Trial name
- NCT00413166
- Testing
- All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.
- Trial name
- NCT02013167
- Testing
- Blinatumomab, Standard of Care Chemotherapy
- Where
- 117 sites in United States, Australia and 19 more
- Volunteers
- 405 people
- Sponsor
- Amgen
Acute Myeloid Leukemia
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
This research study is studying a targeted therapy (a form of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells) as a possible treatment for…
- Trial name
- NCT02560025
- Testing
- Alisertib, Cytarabine, Idarubicin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
- Trial name
- NCT02626338
- Testing
- Crenolanib, Mitoxantrone, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is among the most common hematologic malignancies in adults and accounts for approximately 10,000 deaths in the United States every year. AML is commonly diagnosed in sixth or seventh decades of life.
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT03226418
- Testing
- Cytarabine, Decitabine, Idarubicin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Nebraska
AML
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication…
- Trial name
- NCT02039726
- Testing
- Quizartinib, Salvage Chemotherapy
- Where
- 131 sites in United States, Australia and 17 more
- Volunteers
- 367 people
- Sponsor
- Daiichi Sankyo
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
This clinical trial studies idarubicin, cytarabine, and pravastatin sodium in treating patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01831232
- Testing
- pravastatin sodium, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
The purpose of this study is to: Test the safety of the research study drug, lenalidomide, when given with Idarubicin and Cytarabine See how many respond to combination treatment with lenalidomide, Idarubicin and Cytarabine See…
- Trial name
- NCT00831766
- Testing
- Idarubicin, Cytarabine, Lenalidomide (Revlimid®)
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia (Relapsed/Refractory)
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is currently treated with chemotherapy by combining several drugs with different ways of inhibiting the cell growth.
- Trial name
- NCT02249091
- Testing
- Selinexor, Idarubicin, Cytarabine
- Where
- 3 sites in Germany
- Volunteers
- 42 people
- Sponsor
- GSO Global Clinical Research BV
Acute Myeloid Leukemia
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
This is a phase 1b, dose escalation, study of quizartinib to evaluate the safety profile, the pharmacokinetics, and the recommended dose of quizartinib for subsequent clinical studies of the combination of quizartinib and…
- Trial name
- NCT02834390
- Testing
- Quizartinib, Cytarabine, Idarubicin
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
- Trial name
- NCT02665143
- Testing
- Nintedanib and AML induction
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Acute Myeloid Leukemia
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
This was an open-label pilot study that evaluated the safety and preliminary evidence of a therapeutic effect of dociparstat in conjunction with standard induction and consolidation therapy for acute myeloid leukemia (AML).
- Trial name
- PGX-AML (NCT02056782)
- Testing
- Dociparstat sodium
- Volunteers
- 12 people
- Sponsor
- Jazz Pharmaceuticals
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)